<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189683</url>
  </required_header>
  <id_info>
    <org_study_id>AERO-MC04</org_study_id>
    <nct_id>NCT00189683</nct_id>
  </id_info>
  <brief_title>Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Européenne de Recherche en Oncologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Européenne de Recherche en Oncologie</source>
  <brief_summary>
    <textblock>
      To compare maintenance chemotherapy with Xeloda to control after best response with first
      line chemotherapy in advanced colorectal cancer. Main endpoint is progression free survival.
      A total of 300 patients will be included.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Monitoring</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Xeloda</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic colorectal cancer (confirmed histologically) with objective
             response or stabilization after at least 6 cycles of first line chemotherapy
             (treatment of choice is selected freely by the investigator according to the
             recommendations and consensus in force),

          -  The interval between completion of first line chemotherapy and randomization should
             not exceed 4 weeks

          -  Age&gt;18 years

          -  ECOG status 0 to 2

          -  Biological criteria prior to any chemotherapy:

        Neutrophils&gt;1.5 109 g/l, platelets&gt;100 109/l, haemoglobin&gt;10 g/dl, Creatininaemia&lt;150
        mol/l, bilirubinaemia&lt;2x normal level

          -  Signed informed consent

          -  Life expectancy &gt; 3 months

        Exclusion Criteria:

          -  Metastatic colorectal cancer treated with more than one modality of first line
             chemotherapy (including oral fluoropyrimidines)

          -  Tumour progression after first line chemotherapy or before randomization

          -  Other tumour pathology

          -  Symptomatic cerebral metastases

          -  Any severe uncontrolled disease in addition to colorectal cancer (in particular
             decompensated cardiac failure (LVEF&lt;50%) or coronary insufficiency)

          -  Lack of integrity of the upper GI tract: malabsorption syndrome or major surgery of
             the stomach or the small intestine

          -  Severe renal impairment (creatinine clearance &lt; 30 ml/min)

          -  Severe psychiatric disorder (other than controlled depressive syndrome)

          -  Patient participating in another experiment

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Fabre-Guillevin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AERO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Van Cutsem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BGDO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Polus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BGDO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annie Jouhaud</last_name>
    <phone>+ 33 1 43 77 72 10</phone>
    <email>annie.jouhaud@aero-eu.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>AERO</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Fabre-Guillevin, MD</last_name>
      <phone>+ 33 1 43 77 72 10</phone>
      <email>elizabeth.fabre-guillevin@egp.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

